Article Abstract

Personalised treatment for prostate cancer patients: are we there yet?

Authors: Andrew D. Gillen, Iain J. McEwan

Abstract

Prostate cancer (PCa) is an extremely heterogeneous disease—a small proportion of patients present with rapidly progressing, aggressive disease, referred to as unfavourable-risk PCa; whilst more commonly the disease progresses far more slowly and does not present an immediate health risk (1).